Gemtuzumab ozogamicin aml
Procedure Code Description MECHLORETHAMINE HYDROCHLORIDE, NITROGEN MUSTARD ; , 10 MG INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG METHOTREXATE SODIUM, 5 MG METHOTREXATE SODIUM, 50 MG INJECTION, OXALIPLATIN, 0.5 MG PACLITAXEL, 30 MG PEGASPARGASE, PER SINGLE DOSE VIAL PENTOSTATIN, PER 10 MG PLICAMYCIN, 2.5 MG MITOMYCIN, 5 MG MITOMYCIN, 20 MG MITOMYCIN, 40 MG INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG GEMTUZUMAB OZOGAMICIN, 5MG INJECTION, PEMETREXED, 10 MG RITUXIMAB, 100 MG STREPTOZOCIN, 1 GM THIOTEPA, 15 MG TOPOTECAN, 4 MG TRASTUZUMAB, 10 MG VALRUBICIN, INTRAVESICAL, 200 MG VINBLASTINE SULFATE, 1 MG VINCRISTINE SULFATE, 1 MG VINCRISTINE SULFATE, 2 MG VINCRISTINE SULFATE, 5 MG VINORELBINE TARTRATE, PER 10 MG INJECTION, FULVESTRANT, 25 MG INJECTION, FOSPHENYTOIN, 50 MG INJECTION, TENIPOSIDE, 50 MG INJECTION, INTERFERON BETA-1A, 11 MCG FOR INTRAMUSCULAR USE INJECTION, INTERFERON BETA-1A, 11 MCG FOR SUBCUTANEOUS USE INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML INJECTION, CIMETIDINE HYDROCHLORIDE, 300 MG INJECTION, FAMOTIDINE, 20 MG INJECTION, METRONIDAZOLE, 500 MG INJECTION, NAFCILLIN SODIUM, 2 GRAMS INJECTION, AZTREONAM, 500 MG INJECTION, CEFOTETAN DISODIUM, 500 MG INJECTION, CLINDAMYCIN PHOSPHATE, 300 MG INJECTION, PIPERACILLIN SODIUM, 500 MG INJECTION, PEGYLATED INTERFERON ALFA-2B, 10 MCG PER 0.5 ML INJECTION, EFALIZUMAB, 125 MG INJECTION, PANTOPRAZOLE SODIUM, 40 MG.
1. Walzer PD, Perl DP, Krogstad DJ, et al. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80: 83-93. Burke BA, Cood RA. Pneumocystis carinii infection. Medicine 1973; 52: 23-51. Hughes WT. Pneumocystis carinii pneumonia. N Engi J Med 1977; 297: 1381-1383. Safai B, Cood RA. Kaposi's sarcoma: a review and recent developments. Clin Bull 1980; 10: 62-69.
EditorWe read with interest the article entitled `Volatile anaesthetics and the atmosphere: atmospheric lifetimes and atmospheric effects of halothane, enurane, isourane, desurane and sevourane', as well as the subsequent communication from McCulloch.2 In neither paper did the authors discuss whether the evacuation of waste anaesthetics into the atmosphere is acceptable or whether we should be developing techniques to minimize it. Langbein and colleagues concluded that the relative contribution to global warming of all volatile anaesthetics is in the order of 0.03% of total global emissions and that the contribution to greenhouse warming potential GWP-weighted ; emissions is small.1 Presenting only the magnitude of the relative GWP, however, ignores the fundamental issue that this medical waste
The Company has no present intention of carrying on any businesses or investing in any areas of commercial activity outside of biotechnology. If the research and development which will be funded by the proceeds of the present Offer do not succeed in producing a clinically viable EPF drug for use in humans, so that CBio does not reach the Milestone in its research and development agreement with UniQuest, being the successful completion of the Clinical Phase I trials in humans, the board has no current proposal for further business and would need to review the Companys options at that point. It is possible that the Company would then be wound up.
Gemtuzumab products
Holtappels, R., Thomas, D., Podlech, J., Geginat, G., Steffens, H.-P. & Reddehase, M. J. 2000 ; . The putative natural killer decoy early gene.
27. Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, Paulli M, Meijer CJ, Willemze R: Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favourable prognosis. A European multicenter study of 47 patients. Cancer 71: 2097, 1993 De Vita F, Di Grazia M, Orditura M, Saieva MR. Catalan0 G: Autologous bone marrow transplantation in Ki-l lymphoma with poor prognosis. A case report. Recenti Prog Med 85: 278, 1994 Guglielmi C, Amadori S, Anselmo AP, Baroni CD, Biagini C, Cimino G, Papa G, Mandelli F: Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone F-MACHOP ; . Cancer Invest 5: 159, 1987 Guglielmi C, Amadori S, Martelli M, Dragoni F, Mandelli F: The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: Long-term results. Ann Oncol 2: 365, 1991 Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31360, 1971 32. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 5549, 1982 33. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's Lymphoma. N Engl J Med 329: 987, 1993 Reiter A, Schrappe M, Tiemann M, Parwaresch R, ZimmermannM, Yakisan E, Dopfer R, Bucsky P, Mann G, Gadner H, Riehm H: Successful treatment strategy for Ki-l anaplastic largecell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12: 899, 1994 Sandlund JT, Pui CH, Santana VM, Mahmoud H, Roberts WM, Moms S, Raimondi S, Ribeiro R, Crist WM, Lin JS, Mao I, Berard CW, Hutchison E: Clinical features and treatment outcome for children with CD30 + large-cell non-Hodgkin's lymphoma. J Clin Oncol 12: 895, 1994 Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, Rubie H, Huguet-Riga1 F, Delsol G: Bone marrow involvement in anaplastic large cell lymphoma. J Clin Pathol 103: 82, 1995 and gemzar.
The Truth I + II ; 435 however, I'm going to use this review to look at what went wrong and why. What hurt the season the most was the writers' refusal to let go of what had made the show successful or at least popular ; in years past, thereby sabotaging its prospects for the future. They kept the mythology going when it had clearly run out of gas, having passed up opportunities to resolve it at the end of the seventh or eighth season; they tried to keep Mulder central to the mythology despite David Duchovny's absence; and they insisted on including Scully in every single episode, no matter how perfunctory and irrelevant her appearances seemed in some of the standalones. It's difficult to escape the conclusion that they were thinking as businessmen first and writers second, grasping desperately at whatever might keep the fans watching and in the process creating enormous storytelling difficulties for themselves. Even if they had overcome these difficulties, I'm still not sure it would have worked. The mythology couldn't help but seem repetitive after eight years centered around the same basic concept: aliens exist, the government knows about them, and they have dark designs for the future of the planet. And in terms of characterization, what the series needed most at this point was to develop a new identity centered around Doggett and Reyes, but this proved nearly impossible with so many unresolved issues surrounding Mulder and Scully still lingering. Some fans will say that "The Doggett and Reyes Show" never worked and was doomed to failure from the beginning, but if you ask me, "The Doggett and Reyes Show" was never even properly attempted. Adding to the season's troubles was the fact that, to be quite frank, the writers didn't overcome these storytelling difficulties. In the case of the mythology, they didn't even come close. Many of the season's worst entries were mythology episodes, usually because they were centered around two inherently problematic concepts. The first, of course, would be the alien "supersoldiers". There is hardly a more worn-out clich in genre fiction than supernatural and or paranormal beings who "can't be stopped", and the writers didn't bring any kind of new angle to the idea other than to combine it with the only-slightly-less-worn clich at least for The X-Files ; of the Mysterious Informant Knowle Rohrer at first, and later Shannon McMahon and the Shadow Man ; . Either they were giving ambiguous clues that usually led nowhere, or they were stone-faced enforcers who took a licking and kept on ticking. Suffice it to say that I found these characters thoroughly uninteresting, and the fact that they served as the new "face" of the alien invaders also robbed the show of its most evocative and striking visual motifs, to the point that I was happy just to see a UFO again in "Providence" regardless of its role in the story. The second major conceptual flaw in the mythology this season, and arguably the more serious one, was that Scully's son William was not just a normal human child as implied by last season's "Existence" ; , but in fact possessed abnormal psychokinetic abilities and was of major interest to the aliens and conspirators. Under such a setup, there is of course a temptation for the writers to tug at the audience's heartstrings by putting the child in danger, and the X-Files staff succumbed to it more than once, in the process reducing much of Scully's dialogue to over-the-top "NOT MY BABY!" schtick. Displaying little of the intellectual energy and dedication to truth and justice that we'd come to expect, Scully now only cared about unraveling the conspiracy if it would help her discover something about the nature of her child. Was this "realistic" for her character? Maybe, but it was also rather one-dimensional, especially since Scully didn't seem aware that she had changed since William was born, or if she was we never saw her talk to anyone about it. Not every possible path for a character needs to be traveled, after all, especially if the path ends with Scully giving her son up for adoption on the flimsiest of pretexts, as she did in "William". Granted, the story wasn't working and perhaps the writers had simply decided to jettison it, but they did it such a bizarre and unbelievable way that the final scene might as well have been subtitled, "Writers to Audience: We give up. Sorry". And whatever the reasons, the fact is that absolutely nothing was accomplished by putting the audience through nearly two entire seasons of this "miracle child" melodrama: if they were determined to get rid of William, they should have at least done it in a way that meant something and was true to the characters. Because the writers tied the mythology so closely to William even though they seemed to have no idea what to do with him, the mythology episodes tended to hit the same dull notes over and over again. The supersoldiers would appear, either subtly undermining the agents' investigations or as an open threat, important "revelations" about William would be within Scully's grasp only to evaporate, characters would talk about Mulder but never really explain why he'd taken off and what he hoped to accomplish, and meanwhile there were the usual chases, car accidents, shootings, explosions, decapitations, etc. The "Nothing Important Happened Today" 2-parter and "Provenance" were the worst offenders, though "Trust No 1" wasn't far behind with its absurd attempts to integrate Mulder into the plot by having him send e-mail to Scully and appear from a distance so that his face was obscured. Though there were parts of "William" and "The Truth" that I liked quite a bit, the only mythology episode I could fully recommend was "Providence", largely because it avoided these pitfalls and instead fo.
Gemtuzumab hydrochloride
Gemtuzumab ozogamicin Mylotarg ; induces remission in approximately 30% of relapsed AML patients. We previously demonstrated that gemtuzumab infusion results in near-complete CD33 saturation in peripheral blood, and that saturating gemtuzumab levels result in continuous binding and internalization of gemtuzumab due to renewed CD33 expression. We now demonstrate that a high CD33-antigen load in peripheral blood is an independent adverse prognostic factor, likely due to peripheral consumption of gemtuzumab. Indeed, CD33 saturation in bone marrow is significantly reduced 40-90% saturation ; as compared with CD33 saturation in corresponding peripheral blood samples 90% ; . In vitro, such reduced CD33 saturation levels were strongly related with reduced cell kill. Apparently, high CD33antigen loads in blood consume gemtuzumab and thereby limit its penetration into bone marrow. Consequently CD33 saturation in bone marrow is reduced, which hampers efficient cell kill. Therefore, gemtuzumab should be administered at higher or repeated doses, or, preferably, after reduction of the leukemic cell burden by classical chemotherapy and genotropin
Following, 1285 Cutaneous leishmaniasis, antigen evaluation in the in direct fluorescent antibody test for, 1260 Cutaneous paragonimiasis in man in Honduras, 376 Cysticercosis, Mexican habits predisposing to, 1179 D DALRYMPLE, J. M. , 577 Dasypracta frunctata, togavirus.
For those over 60 years of age. For the majority of patients the role of cytarabine during induction remains controversial and therefore the panel recommends that initial therapy should consist of concomitant anthracycline based chemotherapy and ATRA Category 1 recommendation ; . However for high risk patients the addition of cytarabine may offer some advantage. To minimize early induction mortality due to coagulopathy, patients with a presumptive diagnosis of APL based on morphology, immunophenotype and DIC screen should promptly start ATRA and anthracycline without waiting for molecular confirmation. If the initial clinical diagnosis of APL is not confirmed by cytogenetic findings, ATRA will be discontinued and standard AML induction continued. Recently, there has been interest in eliminating the anthracycline from induction regimens. Estey and colleagues studied an induction regimen combining ATRA and arsenic trioxide in 25 patients with low risk APL; 19 high risk patients were treated using the same regimen combined with gemtuzumab 9 mg m2 on day 1 of induction therapy.15 Complete remission was achieved in 24 of patients with low risk disease and 15 of 19 patients with high risk disease. The authors suggest that ATRA plus arsenic trioxide may be an alternative to chemotherapy in patients with low risk APL. The NCCN guidelines indicate that ATRA plus arsenic trioxide is an alternative for patients who cannot tolerate anthracycline therapy. This induction regimen may be a particular consideration in the 19% of APL cases presenting in patients greater than 60 years old.16 Therapy for APL is often associated with a constellation of symptoms and physiologic abnormalities, including fluid retention, dyspnea, episodic hypotension, pulmonary infiltrates, and pulmonary or pericardial effusions now referred to as "differentiation syndrome". It can occur with both ATRA and arsenic as single agents and gentamicin.
Gemtuzumab ozogamicin aml
A b c Significantly lower cumulative detection probability than the IAEA detection probability and timeliness goal for depleted, natural, and LEU uranium. 50% in 1 year This equates to IAEA detection probability and timeliness goal for 1 significant quantity of depleted, natural, and LEU uranium ; . 20% in 3 months, 50% in 1 year This equates to IAEA detection probability and timeliness goal for 1 significant quantity of spent fuel irradiated material ; . 50% in 1 month, 90% in 1 year This equates to IAEA detection probability and timeliness goal for 1 significant quantity HEU separated Pu ; . Significantly greater cumulative detection probability than the IAEA detection probability and timeliness goal for HEU separated Pu.
Philosophy of Soft Computing Invited ; , Chair: V. Niskanen, Room: D.183 10.10 Ontological Grounding of Fuzzy Theory I. Burhan Turksen 10.27 Scientific Outlook from Soft-Computing Standpoint Vesa Niskanen 10.44 DNA Computing Approach to Optimal Decision Problems Junzo Watada, Satoshi Kojima, Satomi Ueda and Osamu Ono 11.01 On Aristotelian Tradition and Fuzzy Revolution Jorma Mattila 11.18 40 years ago: "Fuzzy Sets" is going to be published Rudolf Seising 11.35 Spatial Knowledge Creation In A Circular World - Perspectives On Logical And Visual Communication In A Social Space Susanne Kratochwil and Josef Benedikt 11.52 A Philosophical Study on Meaning and Fuzzy Sets Tero Joronen and gentian.
From a clinician's perspective there is a great need to develop new treatments for those of our patients who have so far not benefited from the progress made in paediatric oncology and who still have a very poor chance of long term survival. These include patients with relapsed leukaemia, patients with advanced stage sarcomas including Ewing's sarcoma ; and neuroblastoma and certain patients with brain tumours. We are aiming at increasing the number of phase I II studies in children with cancer. Our research in Newcastle spans all areas of drug development from basic biology target identification ; , drug development, preclinical drug testing and pharmacology to phase I II studies in children. The studies will be organised within the national framework provided by the UKCCSG Division of Therapeutics Committee, and Newcastle is one of the phase I II centres accredited by the European Consortium for Innovative Therapies for Children with Cancer ITCC.
Trinity reformed united church of christ is an open, loving, growing church committed to welcoming persons of all ages, races, life status, and beliefs, engaging all in worshiping god, and in serving others while seeking to know god's will and ginger.
204.90-204.91, 205.00 to 208.01, 273.0-273.3 Fluorouracil J9190 140.0 to 199.1, 259.2 Fulvestrant J9395 174.0 to 175.9 Gallium Nitrate J1457 Primary ICD-9 for the malignancy plus 275.42 as Secondary DX Gemcitabine J9201 156.0-156.9, 157.0 to 158.9, 162.2-162.9, 164.2, to 175.9, 179, 181, to 202.98 Gemtuzumab Ozogamicin J9300 205.00 to 207.11 Granisetron Hcl. J1626 787.01, 787.03, 995.20, Anti-emetic chemotherapy-induced ; Idarubicin J9211 204.00-204.11, 205.00-208.01, 238.71-238.79 Ifosfamide J9208 140.0 to 149.9, 157.0-157.9, 160.0-161.9, -164.9, 170.0 to 171.9, 174.0 to 175.9, 180.0 to 183.9, 186.0186.9, 188.0 to 189.0, 194.0-194.9, 195.0, to 202.98, 204.00 to 207.81 Interferon Alpha-1 J9212, Interferon Alpha-2A J9213, Interferon Alpha-2B J9214, Interferon AlphaN3 J9215, Interferon Gamma 1-B J9216 042, 070.51, 070.54, to 149.8, 150.0-150.9, 153.0 to 154.9, 157.0-157.9, 160.0161.9, to 173.9, 176.0-176.9, 180.0-180.9, to 189.3, 191.0191.9, 195.0, to 204.11, 205.00-205.11, 233.7, Irinotecan Hcl. J9206 150.0-152.9, 153.0 to 154.8, 155.1, 159, Leucovorin Calcium J0640 140.0 to 149.9, 151.0-151.9, 153.0 to 154.8, 160.0162.9, 170.0-170.9, to 175.9, 181, 186.9, to 202.98, 236.1 Leuprolide Acetate Depot J1950 3.75 mg one month dose or 11.25 mg 3 month dose covered for the following: 157.0-157.9, 174.0175.9, 182.0, Mechlorethamine J9230 162.2-162.9, 164.1, 197.2, to 202.98, 204.10, 204.11, Melphalan J9245 170.0 to 172.9, 174.0 to 175.9, 182.0 to 183.9, 185, 186.0-186.9.
Gemtuzumab drug
Forest or the regrowth of forest. 2001 Hence, the rights to timber skogsfng ; can be prohibited during a certain time period. Finally, as explained above in subsection 8.2.3.2 regarding the environmental requirements on the reindeer husbandry, the Swedish Board of Agriculture has the authority to issue by-laws on the protection of the natural and cultural environments, and has also used this authority 2002 . The County Administrative Board has been given authority through direct supervision direct tillsyn ; to decide on the injunctions or prohibition necessary to ensure that the provisions in the by-laws are followed. Such injunctions and prohibitions may be decided only if the advice given by the authority has not been followed. In urgent matters or where specific reasons srskilda skl ; apply, the County Administrative Board may without delay decide on an injunction or prohibition. Decisions on injunctions and prohibitions may also impose a fine. 2003 and ginkgo.
MERCURY is published to provide information about Long Beach Memorial Medical Center, Miller Children's Hospital and the Memorial Medical Center Foundation for philanthropic friends, auxiliaries, volunteers, patients, medical staff, employees and visitors. MERCURY highlights medical center programs and patients who have benefited from philanthropic gifts and grants to the Memorial Medical Center Foundation, a 501 c ; 3 charitable organization. Long Beach Memorial Medical Center is a 568-bed, acute care hospital and adjacent Miller Children's Hospital, is a 171-bed acute care hospital. Both are teaching and research facilities committed to providing high quality, cost-effective patient care and are members of the MemorialCare family of hospitals. Memorial Health Services Barry Arbuckle, PhD President and CEO Long Beach Memorial Medical Center Miller Children's Hospital Byron F. Schweigert, PharmD CEO Memorial Medical Center Foundation Donna M. Reckseen President James Normandin Executive Vice President Timothy Jackert, CPA Vice President, Finance Iris Quiroz Director, Corporations Foundations Julie Heggeness, JD Director, Trusts and Estates Mercury Publication Team Donna M. Reckseen Managing Editor Terri Starkman Director, Public Relations Marketing, LBMMC Joni Ramirez Director, Public Relations Marketing, MCH Carol A. Beckerman Editor Dann Froehlich Design Graphic Design Queen Beach Printers, Inc. Printing Sue Perslow Cristina Salvador Scott Windus Photography and gemtuzumab.
In April 2002 from then DeaconessWaltham Hospital and expanded the service dramatically. The agency has had many names since its founding in 1980, when a group of volunteers sought to bring end-oflife care to residents in the Watertown area. As Hospice West, it reached out to AIDS patients by operating the Hospice of Mission Hill, which has since closed, and it later acquired Trinity Hospice of Boston. In Sep and ginseng.
Gemtuzumab pills
Indicate improved outcome in younger adults treated with autologous SCT in first CR.84 The MLL-WT transcript is not expressed in AML blasts with the MLL-PTD.85 Transcriptional reactivation of the MLL-WT allele occurs in response to DNA methyltransferase DNMT ; and or histone deacetylase HDAC ; inhibitors and is associated with enhanced sensitivity to cell death. Therefore, pharmacologic reversal of MLL-WT silencing by demethylating agents and histone deacetylase inhibitors should be investigated in CN-AML patients with the MLL-PTD.85 Mutations of the CEBPA gene The CEBPA gene encodes the C EBP protein, a member of the family of basic region leucine zipper bZIP ; transcription regulators involved in granulopoiesis.86 CEBPA mutations occur in 15-19% of CNAML.60, 61, 87 They confer significantly longer CRD and OS.60, 61 Mutations of the NPM1 gene NPM1 encodes nucleophosmin, a nucleus-cytoplasm shuttling protein, involed in preventing nucleolar protein aggregation, regulation of ribosomal protein assembly and their nucleocytoplasmic transport, the initiation of centrosome duplication and the regulation of the p53 and Arf tumor-suppressor pathways.88 Its exact role in oncogenesis is controversial. Nucleophosmin is most prominent in the nucleus, but in patients with mutated NPM1, nucleophosmin shows cytoplasmic expression that may interfere with its normal functions.89 NPM1 mutations are found in 45-64% of CN-AML patients, 55, 64, 90-92 and usually predict outcome only in the context of other markers. Coexistence of NPM1 mutations with MLL-PTD and CEBPA mutations is rare, but about 40% of NPM1 mutated patients are also FLT3-ITD-positive. The poor outcome of patients with FLT3-ITD is relatively unaffected by the presence or absence of NPM1 mutations. However, among patients without FLT3-ITD, those with NPM1 mutations have a significantly better response to induction therapy, disease-free survival DFS ; , RFS, EFS and OS.55, 64, 92 Mutations of the WT1 gene WT1 encodes a zinc finger DNA-binding protein that continually shuttles between the nucleus and cytoplasm.93 Depending on cellular context, it can also be involved in transcriptional activation or repression. Its role in hematopoiesis and leukemogenesis is not well established, although it has been suggested that impairment of WT1 protein function could promote stem cell proliferation and induce a block in differentiation.94 In a recent study of CN
Gemtuzumab medicine
Cranial nerves 2-12 sensorimotor reflex examination, antimalarial side effect, warshaw collection of business americana, section township range converter and precedex infusion dose. Trileptal cost, butalbital rebound, cruciate graft and venlafaxine effexor xr or lamictal effexor.
Gemtuzumab alcohol
Vemtuzumab, gemtuzuman, gemtuzkmab, gemtuzzumab, egmtuzumab, gemtuaumab, gemtuuzmab, temtuzumab, gemtuzuamb, gemtuz7mab, gemtuzuab, gemtzumab, gemtuzimab, gemthzumab, gejtuzumab, gemtuzumaab, gemhuzumab, gemtuzumah, gemtizumab, femtuzumab.
Gemtuzumab review
Gemtuzumab products, gemtuzumab hydrochloride, gemtuzumab ozogamicin aml, gemtuzumab drug and gemtuzumab pills. Gemtuzumab medicine, gemtuzumab alcohol, gemtuzumab review and gemtuzumab cream or gemtuzumab ozogamycin.
|
